{
    "clinical_study": {
        "@rank": "28511", 
        "acronym": "URIPRENE", 
        "arm_group": {
            "arm_group_label": "Interventional", 
            "arm_group_type": "Experimental", 
            "description": "Placement of ureteral stent following post-ureteroscopy"
        }, 
        "brief_summary": {
            "textblock": "A prospective, single-center, single-arm, trial to demonstrate safety and device performance\n      of the ADVA-Tec Uriprene\u2122 Degradable Temporary Ureteral Stent.  This is a first-in-man\n      clinical study in a small human population."
        }, 
        "brief_title": "Feasibility Study of the Uriprene Stent Following Uncomplicated Ureteroscopy", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Unilateral Ureteral Stone", 
            "Renal Stone Fragments \u2264 2mm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Calculi", 
                "Kidney Calculi", 
                "Ureteral Calculi", 
                "Ureterolithiasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Objective:  To assess the safety and feasibility of the Uriprene\u00ae Stent by assessing\n      the time to complete degradation or the passage of stent fragments from the bladder by\n      radiological assessment.\n\n      Subject Population:  Patients with clinical symptoms consistent with unilateral ureteral or\n      renal stone fragments \u2264 2mm, post-uncomplicated ureteroscopy (UURS)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients who are > 18, < 80 years of age; inclusive of males and females.\n\n          2. Patients with unilateral ureteral or renal stone fragments < 2mm, post-uncomplicated\n             ureteroscopy (UURS).\n\n          3. Patients with a height and body size able to accommodate a 20, 22, 24, 26, 28, or 30\n             mm long ureteral stent, as judged by the Investigator.\n\n          4. Patients with the ability to understand the requirements of the study, who have\n             provided written informed consent, and who have agreed to return for the required\n             follow-up assessments.\n\n        Exclusion Criteria:\n\n          1. Patients with a known contraindication for treatment with the Uriprene\u00ae Stent.\n\n          2. Patients with a history of an anatomical abnormality of the urinary tract.\n\n          3. Patients with a known upper or lower urinary tract infection at the time of stent\n             insertion.\n\n          4. Patients with known renal insufficiency or chronic impairment.\n\n          5. Any condition, in the opinion of the investigator, in whom patients would not be\n             eligible for treatment with the Uriprene\u00ae Stent.\n\n          6. Pregnant or lactating women, or women of childbearing potential who do not employ a\n             reliable method of contraception as judged by the Investigator.\n\n          7. Patients who consume more than 14 drinks of alcohol per week (as this may affect\n             degradation of the stent).\n\n          8. Presence of ureteral blockage or stricture\n\n          9. After failed guide wire placement or failed ureteroscopic access\n\n         10. Impacted ureteral stones still in place\n\n         11. Patients predisposed to urinary stasis e.g. neurogenic bladder, bladder outlet\n             obstruction, known pregnancy\n\n         12. Patients with a solitary kidney\n\n         13. Presence of ureteral fistula\n\n         14. Presence of ureteral tumor\n\n         15. Presence of extrinsic compression of the ureter\n\n         16. Urinary tract infection\n\n         17. Staghorn calculi"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032316", 
            "org_study_id": "CLIN 14-32-002"
        }, 
        "intervention": {
            "arm_group_label": "Interventional", 
            "description": "Renal stent placed after uncomplicated uteroscopy", 
            "intervention_name": "Post-Ureteroscopy ADVA-Tec Uriprene\u2122 Degradable Temporary Ureteral Stent", 
            "intervention_type": "Device", 
            "other_name": "Renal ureteral stent"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Renal Stone", 
            "Ureteroscopy", 
            "Ureteral Stent", 
            "post-uncomplicated ureteroscopy", 
            "UURS"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "email": "ben.chew@ubc.ca", 
                "last_name": "Ben Chew, MD", 
                "phone": "+1 (604) 875-5046"
            }, 
            "facility": {
                "address": {
                    "city": "Vancouver", 
                    "country": "Canada", 
                    "state": "British Columbia"
                }, 
                "name": "University of British Columbia"
            }, 
            "investigator": {
                "last_name": "Ben Chew, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "URIPRENE: Feasibility Study to Evaluate the Preliminary Safety and Effectiveness of the Uriprene Stent Following Uncomplicated Ureteroscopy", 
        "overall_contact": {
            "email": "jcartledge@adva-tec.com", 
            "last_name": "Jennifer Cartledge", 
            "phone": "+ (864) 506-0097"
        }, 
        "overall_official": {
            "affiliation": "University of British Columbia", 
            "last_name": "Ben Chew, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite of new-onset serious adverse event(s) including death, infection, the occurrence of surgery, re-hospitalization and or repeat hospitalization related to the device, or device related injury of the ureter.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032316"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Technical success of the device defined as complete degradation of the stent within 90 days, as measured by radiology", 
                "measure": "Technical Success", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Degree of comfort and pain as measured by the Pain, Symptom, and Satisfaction Questionnaire", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }
        ], 
        "source": "Adva-Tec", 
        "sponsors": {
            "collaborator": {
                "agency": "University of British Columbia", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Adva-Tec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}